(EMBC) Embecta - NASDAQ
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 184m USD | Total Return: -66.8% in 12m
Avg Turnover: 6.29M
EPS Trend: -22.7%
Qual. Beats: -1
Rev. Trend: -82.7%
Qual. Beats: -1
Warnings
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
Embecta Corp. (EMBC) is a medical device manufacturer specializing in diabetes management solutions, including pen needles, syringes, and safety injection devices. Headquartered in Parsippany, New Jersey, the company operates both domestically and internationally, distributing products primarily through wholesalers and medical supply distributors.
The company operates within the Health Care Supplies sub-industry, a sector characterized by high recurring revenue due to the chronic, daily nature of insulin delivery requirements. As a pure-play diabetes care business spun off from Becton Dickinson, Embecta maintains a legacy infrastructure dating back to 1924, focusing on the large-scale production of injection hardware.
Investors may find it useful to review ValueRay for further data on the companys valuation metrics. The business model relies on high-volume manufacturing and established supply chain relationships to serve a global patient base requiring lifelong medication delivery tools.
- High global demand for insulin delivery devices sustains core revenue growth
- FDA clearance of proprietary insulin patch pump expands total addressable market
- High debt levels and interest expenses impact net income and valuation
- Pricing pressure from government health programs reduces gross profit margins
- Supply chain disruptions and manufacturing costs affect operational efficiency levels
| Net Income: 111.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 16.34 > 1.0 |
| NWC/Revenue: 34.61% < 20% (prev 35.58%; Δ -0.97% < -1%) |
| CFO/TA 0.21 > 3% & CFO 213.5m > Net Income 111.9m |
| Net Debt (1.20b) to EBITDA (322.2m): 3.74 < 3 |
| Current Ratio: 2.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago 0.50% < -2% |
| Gross Margin: 62.52% > 18% (prev 63.70%; Δ -1.17% > 0.5%) |
| Asset Turnover: 97.00% > 50% (prev 96.37%; Δ 0.63% > 0%) |
| Interest Coverage Ratio: 2.71 > 6 (EBIT TTM 269.0m / Interest Expense TTM 99.4m) |
| A: 0.35 (Total Current Assets 608.1m - Total Current Liabilities 247.3m) / Total Assets 1.03b |
| B: -0.41 (Retained Earnings -424.7m / Total Assets 1.03b) |
| C: 0.25 (EBIT TTM 269.0m / Avg Total Assets 1.07b) |
| D: -0.38 (Book Value of Equity -626.1m / Total Liabilities 1.66b) |
| Altman-Z'' = 2.24 = BBB |
| DSRI: 0.75 (Receivables 147.1m/202.6m, Revenue 1.04b/1.08b) |
| GMI: 1.02 (GM 63.70% / 62.52%) |
| AQI: 0.91 (AQ_t 0.18 / AQ_t-1 0.20) |
| SGI: 0.97 (Revenue 1.04b / 1.08b) |
| TATA: -0.10 (NI 111.9m - CFO 213.5m) / TA 1.03b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at USD 3.11 with a total of 11,422,082 shares traded.
Over the past week, the price has changed by +0.97%,
over one month by +7.57%,
over three months by -65.80% and
over the past year by -66.84%.
Embecta has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold EMBC.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 4 | 28.6% |
P/E Trailing = 1.6402
P/S = 0.1764
P/B = 2.6134
Revenue TTM = 1.04b USD
EBIT TTM = 269.0m USD
EBITDA TTM = 322.2m USD
Long Term Debt = 1.32b USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 31.3m
Net Debt = 1.20b USD (calculated: Debt 1.39b - CCE 184.9m)
Enterprise Value = 1.39b USD (183.9m + Debt 1.39b - CCE 184.9m)
Interest Coverage Ratio = 2.71 (Ebit TTM 269.0m / Interest Expense TTM 99.4m)
EV/FCF = 6.78x (Enterprise Value 1.39b / FCF TTM 204.7m)
FCF Yield = 14.75% (FCF TTM 204.7m / Enterprise Value 1.39b)
FCF Margin = 19.64% (FCF TTM 204.7m / Revenue TTM 1.04b)
Net Margin = 10.73% (Net Income TTM 111.9m / Revenue TTM 1.04b)
Gross Margin = 62.52% ((Revenue TTM 1.04b - Cost of Revenue TTM 390.7m) / Revenue TTM)
Gross Margin QoQ = 56.45% (prev 67.23%)
Tobins Q-Ratio = 1.35 (Enterprise Value 1.39b / Total Assets 1.03b)
Interest Expense / Debt = 7.16% (Interest Expense 99.4m / Debt 1.39b)
Taxrate = 34.02% (57.7m / 169.6m)
NOPAT = 177.5m (EBIT 269.0m * (1 - 34.02%))
Current Ratio = 2.46 (Total Current Assets 608.1m / Total Current Liabilities 247.3m)
Debt / Equity = -2.22 (negative equity) (Debt 1.39b / totalStockholderEquity, last quarter -626.1m)
Debt / EBITDA = 3.74 (Net Debt 1.20b / EBITDA 322.2m)
Debt / FCF = 5.88 (Net Debt 1.20b / FCF TTM 204.7m)
Total Stockholder Equity = -639.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.41% (Net Income 111.9m / Total Assets 1.03b)
RoE = -17.49% (negative equity) (Net Income TTM 111.9m / Total Stockholder Equity -639.9m)
RoCE = 39.73% (EBIT 269.0m / Capital Employed (Equity -639.9m + L.T.Debt 1.32b))
RoIC = 23.89% (NOPAT 177.5m / Invested Capital 742.9m)
WACC = 4.89% (E(183.9m)/V(1.57b) * Re(6.15%) + D(1.39b)/V(1.57b) * Rd(7.16%) * (1-Tc(0.34)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.66 | Cagr: 0.98%
[DCF] Terminal Value 77.97% ; FCFF base≈138.7m ; Y1≈159.0m ; Y5≈234.0m
[DCF] Fair Price = 39.06 (EV 3.52b - Net Debt 1.20b = Equity 2.32b / Shares 59.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -22.66 | EPS CAGR: -2.73% | SUE: -1.28 | # QB: -1
Revenue Correlation: -82.71 | Revenue CAGR: -2.19% | SUE: -1.57 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.27 | Chg30d=-67.58% | Revisions=-50% | Analysts=4
EPS current Year (2026-09-30): EPS=1.59 | Chg30d=-43.43% | Revisions=-50% | GrowthEPS=-46.0% | GrowthRev=-5.4%
EPS next Year (2027-09-30): EPS=1.74 | Chg30d=-39.58% | Revisions=-50% | GrowthEPS=+9.3% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -50%